#South Korea #Seoul #Seegene #CURECA™ #PCR Automation

CURECA™: A New Era in PCR Automation

In the evolving landscape of molecular diagnostics, Seegene Inc. has made significant strides with its innovative CURECA™ system, recently showcased at the ESCMID Global 2025 in Vienna. This pioneering platform is tailored to fully automate the PCR (Polymerase Chain Reaction) process, enhancing accuracy while reducing manual labor in laboratories.

Seegene's CURECA™ system addresses the complete PCR workflow - from sample preparation to results evaluation. The modular system is engineered to process a variety of sample types, such as stool, urine, blood, and sputum, automatically carrying out the necessary protocols after sample loading. This feature is particularly critical in environments where efficient turnaround times and streamlined workflows are paramount.

Highlights from the ESCMID Global 2025 Presentation

During the ESCMID event, the CURECA™ concept sparked considerable interest among over 2,300 attendees, drawing attention from healthcare professionals and laboratory experts across nations including Italy, Spain, Germany, and France. Notably, Young-Seag Baeg, Seegene's head of Strategy and Planning, presented the system, emphasizing its transformative potential for laboratories facing staffing challenges and increasing workloads.

Feedback from industry experts was overwhelmingly positive, with many remarking on the potential for CURECA™ to eliminate human error prevalent in manual processes, thus ensuring reliable testing results even amid personnel shortages. One participant highlighted that, “CURECA™ could represent a true paradigm shift, changing the way we handle complex sample preparations.”

Flexibility and Customization in Laboratory Settings

The core component of CURECA™ is the Customizable Pre-treatment System (CPS), designed to automate both sample loading and pre-treatment processes for various diagnostic needs. This modular approach allows labs to tailor the CURECA™ system to their spatial and operational requirements, promoting flexibility within diverse laboratory environments. The CPS module is pivotal as it supports multiple diagnostic fields, including clinical chemistry and immunology.

In addition to the CPS, Seegene introduced the Primary Sample Aliquot System (PAS), which simplifies workflows by allowing the direct dispensing of primary samples, further enhancing operational efficiencies. Collectively, these innovations align with Seegene's vision of a fully integrated PCR automation process, aptly named CEFA (Customizable Expandable Full Automation).

Industry Anticipation and Future Integrations

Experts at ESCMID expect that the implementation of CURECA™ could significantly reduce turnaround times (TAT) due to its adaptable software that aligns workflows with operational deadlines. Notably, in the context of diagnostics for sexually transmitted infections (STIs), the CPS could alleviate the manual workload associated with managing numerous sample tubes, thus optimizing routine laboratory operations.

Design and Efficiency Benefits

The seamless design of CURECA™ not only addresses the diverse needs of laboratories but also maximizes space utility, allowing configurations based on specific laboratory layouts. This aspect has been heralded as a critical component in enhancing operational effectiveness, reflecting a demand for innovative solutions that prioritize high-quality outcomes while minimizing dependence on standardized lab configurations.

Seegene's founder and CEO, Jong-Yoon Chun, underscored the global enthusiasm for CURECA™, stating, “The enthusiastic reception of our concept video illustrates the strong demand for next-generation diagnostic solutions.” This enthusiasm appears well-founded, as the implications of CURECA™ extend beyond mere efficiency; they represent a shift towards a more consistent, accurate, and streamlined approach to PCR diagnostics.

Conclusion: The Future of Diagnostic Laboratories

Seegene's advancements via CURECA™ herald a transformative chapter in the realm of molecular diagnostics. With more than two decades of expertise in PCR technologies, the company is poised to redefine diagnostic processes globally. By continuing to innovate and respond to the evolving needs of healthcare, Seegene aims to create a future where reliable, efficient diagnosis is accessible to all.

For further information, please visit Seegene’s website and follow their latest updates on LinkedIn.